Negative Regulation of the Tumor Suppressor P53 Gene by MicroRNAs

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2010 Oct 12

PMID 20935678

Citations 148

Authors

M Kumar

Z Lu

A A L Takwi

W Chen

N S Callander

K S Ramos

K H Young

Y Li

Affiliations

Soon will be listed here.

Abstract

The tumor suppressor p53, encoded by the TP53 gene, is recognized as the guardian of the human genome because it regulates many downstream genes to exercise its function in cell cycle and cell death. Recent studies have revealed that several microRNAs (miRNAs) are important components of the p53 tumor suppressor network with miR-125b and miR-504 directly targeting TP53. In this study, we use a screening method to identify that two miRNAs (miR-25 and miR-30d) directly target the 3'UTR of TP53 to downregulate p53 protein levels and reduce the expression of genes that are transcriptionally activated by p53. Correspondingly, both miR-25 and miR-30d adversely affect apoptotic cell death, cell cycle arrest and cellular senescence. Inhibition of either miR-25 or miR-30d expression increases endogenous p53 expression and elevates cellular apoptosis in several cell lines, including one from multiple myeloma that has little TP53 mutations. Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d.

Citing Articles

Research progress on the regulatory mechanism of cell senescence in arsenic toxicity: a systematic review.

Gu Y, Qiu Y, Li Y, Wen W Toxicol Res (Camb). 2024; 13(4):tfae136.

PMID: 39184219 PMC: 11339171. DOI: 10.1093/toxres/tfae136.

How MicroRNAs Command the Battle against Cancer.

Wu H, Leng S, Sergi C, Leng R Int J Mol Sci. 2024; 25(11).

PMID: 38892054 PMC: 11172831. DOI: 10.3390/ijms25115865.

Differential microRNA Expression Analysis in Patients with HPV-Infected Ovarian Neoplasms.

Jarych D, Mikulski D, Wilczynski M, Wilczynski J, Kania K, Hareza D Int J Mol Sci. 2024; 25(2).

PMID: 38255835 PMC: 10815566. DOI: 10.3390/ijms25020762.

The Clinical Significance of MicroRNAs in Colorectal Cancer Signaling Pathways: A Review.

Michas A, Michas V, Anagnostou E, Galanopoulos M, Tolia M, Tsoukalas N Glob Med Genet. 2023; 10(4):315-323.

PMID: 38025193 PMC: 10665125. DOI: 10.1055/s-0043-1777094.

Vascular Ageing: Mechanisms, Risk Factors, and Treatment Strategies.

Ya J, Bayraktutan U Int J Mol Sci. 2023; 24(14).

PMID: 37511296 PMC: 10380571. DOI: 10.3390/ijms241411538.

References

Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View

Mayer B, Oberbauer R . Mitochondrial regulation of apoptosis. News Physiol Sci. 2003; 18:89-94. DOI: 10.1152/nips.01433.2002. View

Park S, Lee J, Ha M, Nam J, Kim V . miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol. 2008; 16(1):23-9. DOI: 10.1038/nsmb.1533. View

Xiong W, Wu X, Starnes S, Johnson S, Haessler J, Wang S . An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008; 112(10):4235-46. PMC: 2581979. DOI: 10.1182/blood-2007-10-119123. View

Le M, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V . MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 2009; 23(7):862-76. PMC: 2666337. DOI: 10.1101/gad.1767609. View

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

Johnson S, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A . RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5):635-47. DOI: 10.1016/j.cell.2005.01.014. View

Petrocca F, Visone R, Onelli M, Shah M, Nicoloso M, De Martino I . E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008; 13(3):272-86. DOI: 10.1016/j.ccr.2008.02.013. View

Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown J . Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998; 282(5393):1497-501. DOI: 10.1126/science.282.5393.1497. View

10.

Voeller H, Sugars L, Pretlow T, Gelmann E . p53 oncogene mutations in human prostate cancer specimens. J Urol. 1994; 151(2):492-5. DOI: 10.1016/s0022-5347(17)35000-0. View

11.

Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N . Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007; 26(5):731-43. DOI: 10.1016/j.molcel.2007.05.017. View

12.

Bommer G, Gerin I, Feng Y, Kaczorowski A, Kuick R, Love R . p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007; 17(15):1298-307. DOI: 10.1016/j.cub.2007.06.068. View

13.

Bartel D . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-33. PMC: 3794896. DOI: 10.1016/j.cell.2009.01.002. View

14.

Lewis B, Burge C, Bartel D . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20. DOI: 10.1016/j.cell.2004.12.035. View

15.

Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel P, Chesi M . Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004; 64(4):1546-58. DOI: 10.1158/0008-5472.can-03-2876. View

16.

Vogelstein B, Lane D, Levine A . Surfing the p53 network. Nature. 2000; 408(6810):307-10. DOI: 10.1038/35042675. View

17.

Voorhoeve P, le Sage C, Schrier M, Gillis A, Stoop H, Nagel R . A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006; 124(6):1169-81. DOI: 10.1016/j.cell.2006.02.037. View

18.

Kan T, Sato F, Ito T, Matsumura N, David S, Cheng Y . The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology. 2009; 136(5):1689-700. PMC: 2887605. DOI: 10.1053/j.gastro.2009.02.002. View

19.

John B, Enright A, Aravin A, Tuschl T, Sander C, Marks D . Human MicroRNA targets. PLoS Biol. 2004; 2(11):e363. PMC: 521178. DOI: 10.1371/journal.pbio.0020363. View

20.

Ventura A, Kirsch D, McLaughlin M, Tuveson D, Grimm J, Lintault L . Restoration of p53 function leads to tumour regression in vivo. Nature. 2007; 445(7128):661-5. DOI: 10.1038/nature05541. View